Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Diabetes

  Free Subscription


Articles published in Diabetes Obes Metab

Retrieve available abstracts of 204 articles:
HTML format
Text format



Single Articles


    March 2017
  1. KULKARNI M, Foraker RE, McNeill AM, Girman C, et al
    Evaluation of the Modified FINDRISC Diabetes Score to Identify Individuals at High Risk for Diabetes among Middle-aged White and Black ARIC Study Participants.
    Diabetes Obes Metab. 2017 Mar 21. doi: 10.1111/dom.12949.
    PubMed     Text format     Abstract available


  2. STAELS F, Moyson C, Mathieu C
    Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
    Diabetes Obes Metab. 2017 Mar 20. doi: 10.1111/dom.12948.
    PubMed     Text format     Abstract available


  3. GARG M, Ghanim H, Kuhadiya ND, Green K, et al
    Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 17. doi: 10.1111/dom.12944.
    PubMed     Text format     Abstract available


  4. DU J, Liang L, Fang H, Xu F, et al
    Efficacy and Safety of Saxagliptin Compared with Acarbose in Chinese Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: Results of a Phase IV Open-Label Randomized Controlled Study (The SMART Study).
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12942.
    PubMed     Text format     Abstract available


  5. VAN RAALTE DH, Verchere CB
    Improving glycemic control in type 2 diabetes: stimulate insulin secretion or provide beta-cell rest?
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12935.
    PubMed     Text format     Abstract available


  6. HEISE T, Norskov M, Nosek L, Kaplan K, et al
    Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes.
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12938.
    PubMed     Text format     Abstract available


  7. SALASTEKAR N, Desai T, Hauser T, Schaefer EJ, et al
    Salsalate Improves Glycemia in Overweight Persons With Diabetes Risk Factors of Stable Statin-Treated Cardiovascular Disease: a 30-month Randomized Placebo-Controlled Trial.
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12940.
    PubMed     Text format     Abstract available


  8. POZZILLI P, Norwood P, Jodar E, Davies MJ, et al
    A placebo-controlled, randomised trial of the addition of once weekly GLP-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Diabetes Obes Metab. 2017 Mar 14. doi: 10.1111/dom.12937.
    PubMed     Text format     Abstract available


  9. BOULANGER M, Al-Shahi Salman R, Kerssens J, Wild SH, et al
    Association between diabetes mellitus and incidence and case-fatality after stroke due to intracerebral haemorrhage: a retrospective population-based cohort study.
    Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12934.
    PubMed     Text format     Abstract available


  10. TERAUCHI Y, Yamada Y, Ishida H, Ohsugi M, et al
    The efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients aged 60 years or older with type 2 diabetes mellitus (START-J trial).
    Diabetes Obes Metab. 2017 Mar 9. doi: 10.1111/dom.12933.
    PubMed     Text format     Abstract available


  11. FLORY J, Stempniewicz N, Keating S, Gerhard T, et al
    Comparative Adherence to Diabetes Drugs: An Analysis of Electronic Health Records and Claims Data.
    Diabetes Obes Metab. 2017 Mar 7. doi: 10.1111/dom.12931.
    PubMed     Text format     Abstract available


  12. UMPIERREZ G, O'Neal D, DiGenio A, Goldenberg R, et al
    Lixisenatide reduces glycemic variability in insulin-treated patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Mar 3. doi: 10.1111/dom.12930.
    PubMed     Text format     Abstract available


  13. MAURICIO D, Meneghini L, Seufert J, Liao L, et al
    Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
    Diabetes Obes Metab. 2017 Mar 2. doi: 10.1111/dom.12927.
    PubMed     Text format     Abstract available


  14. STADLER M, Bollow E, Fritsch M, Kerner W, et al
    Prevalence of Elevated Liver Enzymes in Adults with Type 1 Diabetes: a Multicenter Analysis of the German/Austrian DPV Database.
    Diabetes Obes Metab. 2017 Mar 2. doi: 10.1111/dom.12929.
    PubMed     Text format     Abstract available


    February 2017
  15. DE BOER SA, Heerspink HJ, Juarez Orozco LE, van Roon AM, et al
    Effect of linagliptin on pulse wave velocity in early type 2 diabetes (RELEASE): a randomized, double-blind, controlled 26-week trial.
    Diabetes Obes Metab. 2017 Feb 28. doi: 10.1111/dom.12925.
    PubMed     Text format     Abstract available


  16. TANG H, Li D, Zhang J, Li Y, et al
    Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Feb 27. doi: 10.1111/dom.12917.
    PubMed     Text format     Abstract available


  17. PENG XV, Marcinak JF, Raanan MG, Cao C, et al
    Combining the GPR40 agonist fasiglifam with sitagliptin improves glycemic control in patients with type 2 diabetes with or without metformin: a randomized, 12-week trial.
    Diabetes Obes Metab. 2017 Feb 27. doi: 10.1111/dom.12921.
    PubMed     Text format     Abstract available


  18. LIAN JX, McGhee SM, So C, Chau J, et al
    Five-year cost-effectiveness of Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Feb 23. doi: 10.1111/dom.12919.
    PubMed     Text format     Abstract available


  19. ALBER A, Bronden A, Knop FK
    Short-acting GLP-1 receptor agonists as add-on to insulin therapy in type 1 diabetes - a review.
    Diabetes Obes Metab. 2017 Feb 17. doi: 10.1111/dom.12911.
    PubMed     Text format     Abstract available


  20. PAUL SK, Owusu Adjah ES, Samanta M, Patel K, et al
    Comparison of body mass index at diagnosis of diabetes in a multiethnic population: a case-control study with matched non-diabetic controls.
    Diabetes Obes Metab. 2017 Feb 17. doi: 10.1111/dom.12915.
    PubMed     Text format     Abstract available


  21. LEITER LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, et al
    Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12909.
    PubMed     Text format     Abstract available


  22. ABERER F, Hajnsek M, Rumpler M, Zenz S, et al
    Evaluation of Subcutaneous Glucose Monitoring Systems under Routine Environmental Conditions in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12907.
    PubMed     Text format     Abstract available


  23. GADDE KM, Vetter ML, Iqbal N, Hardy E, et al
    Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study.
    Diabetes Obes Metab. 2017 Feb 16. doi: 10.1111/dom.12908.
    PubMed     Text format     Abstract available


  24. BERGMARK BA, Cannon CP, White WB, Jarolim P, et al
    Baseline Adiponectin Concentration and Clinical Outcomes among Patients with Diabetes and Recent Acute Coronary Syndrome in the EXAMINE Trial.
    Diabetes Obes Metab. 2017 Feb 14. doi: 10.1111/dom.12905.
    PubMed     Text format     Abstract available


  25. KAZDA CM, Frias J, Foga I, Cui X, et al
    Treatment with the Glucagon Receptor Antagonist LY2409021 Increases Ambulatory Blood Pressure in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Feb 13. doi: 10.1111/dom.12904.
    PubMed     Text format     Abstract available


  26. SUCHER S, Markova M, Hornemann S, Pivovarova O, et al
    A comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes - a randomized clinical trial.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12901.
    PubMed     Text format     Abstract available


  27. ALATORRE C, Fernandez Lando L, Yu M, Brown K, et al
    Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with GLP-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared to Exenatide QW and Liraglutide.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12902.
    PubMed     Text format     Abstract available


  28. KRAMER CK, Zinman B, Choi H, Connelly PW, et al
    Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Diabetes Obes Metab. 2017 Feb 9. doi: 10.1111/dom.12858.
    PubMed     Text format     Abstract available


  29. KADOWAKI T, Inagaki N, Kondo K, Nishimura K, et al
    Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomised, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Feb 8. doi: 10.1111/dom.12898.
    PubMed     Text format     Abstract available


    January 2017
  30. RATHMANN W, Strassburger K, Bongaerts B, Bobrov P, et al
    Impact of Insulin Sensitivity, Beta-cell Function and Glycemic Control on Initiation of Second-Line Glucose-Lowering Treatment in Newly Diagnosed Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 27. doi: 10.1111/dom.12894.
    PubMed     Text format     Abstract available


  31. GRAY SG, McGuire T, Cohen N, Little PJ, et al
    The emerging role of Metformin in Gestational Diabetes Mellitus.
    Diabetes Obes Metab. 2017 Jan 27. doi: 10.1111/dom.12893.
    PubMed     Text format     Abstract available


  32. ANHOLM C, Kumarathurai P, Pedersen LR, Nielsen OW, et al
    Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12891.
    PubMed     Text format     Abstract available


  33. HUNT B, Vega-Hernandez G, Valentine WJ, Kragh N, et al
    Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12890.
    PubMed     Text format     Abstract available


  34. HARRIS SB, Kocsis G, Prager R, Ridge T, et al
    Safety and Efficacy of IDegLira Titrated Once Weekly versus Twice Weekly in Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Randomized Clinical Trial.
    Diabetes Obes Metab. 2017 Jan 26. doi: 10.1111/dom.12892.
    PubMed     Text format     Abstract available


  35. NYSTROM T, Bodegard J, Nathanson D, Thuresson M, et al
    Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients.
    Diabetes Obes Metab. 2017 Jan 24. doi: 10.1111/dom.12889.
    PubMed     Text format     Abstract available


  36. TERRA SG, Focht K, Davies M, Frias J, et al
    A Phase 3, Efficacy and Safety Study of Ertugliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone.
    Diabetes Obes Metab. 2017 Jan 24. doi: 10.1111/dom.12888.
    PubMed     Text format     Abstract available


  37. STORGAARD H, Cold F, Gluud LL, Vilsboll T, et al
    Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12885.
    PubMed     Text format     Abstract available


  38. JI L, Zhang P, Zhu D, Li X, et al
    Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12886.
    PubMed     Text format     Abstract available


  39. VON SCHOLTEN BJ, Persson F, Rosenlund S, Eugen-Olsen J, et al
    Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial.
    Diabetes Obes Metab. 2017 Jan 20. doi: 10.1111/dom.12884.
    PubMed     Text format     Abstract available


  40. HENRY RR, Dandona P, Pettus J, Mudaliar S, et al
    Dapagliflozin in Patients with Type 1 Diabetes: A post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a Phase IIa pilot study.
    Diabetes Obes Metab. 2017 Jan 18. doi: 10.1111/dom.12882.
    PubMed     Text format     Abstract available


  41. RIZZO M, Rizvi AA, Sesti G
    Cardiovascular Effects of GLP-1 Receptor Agonist Therapies in Patients with Type-1 Diabetes.
    Diabetes Obes Metab. 2017 Jan 18. doi: 10.1111/dom.12883.
    PubMed     Text format    


  42. HAIDAR A, Messier V, Legault L, Ladouceur M, et al
    Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: an open-label, randomised, crossover, controlled trial.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12880.
    PubMed     Text format     Abstract available


  43. KIRK RK, Pyke C, von Herrath MG, Hasselby JP, et al
    Immunohistochemical Assessment of Glucagon-like Peptide 1 Receptor (GLP-1R) Expression in the Pancreas of Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12879.
    PubMed     Text format     Abstract available


  44. TSUJIMOTO T, Sugiyama T, Kajio H
    Effects of beta-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12878.
    PubMed     Text format     Abstract available


  45. GOLDENBERG R, Gantz I, Andryuk PJ, O'Neill EA, et al
    Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled
    Diabetes Obes Metab. 2017 Jan 17. doi: 10.1111/dom.12832.
    PubMed     Text format     Abstract available


  46. DESAI M, Yavin Y, Balis D, Sun D, et al
    Renal Safety of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Patients With Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2017 Jan 12. doi: 10.1111/dom.12876.
    PubMed     Text format     Abstract available


  47. JI L, Li L, Kuang J, Yang T, et al
    Efficacy and safety of fixed-dose combination therapy alogliptin plus metformin in Asian patients with type 2 diabetes: a phase 3 trial.
    Diabetes Obes Metab. 2017 Jan 11. doi: 10.1111/dom.12875.
    PubMed     Text format     Abstract available


  48. DASGUPTA K, Rosenberg E, Joseph L, Cooke AB, et al
    Physician Step prescription and Monitoring to improve ARTERial health (SMARTER): a randomized controlled trial in type 2 diabetes and hypertension.
    Diabetes Obes Metab. 2017 Jan 11. doi: 10.1111/dom.12874.
    PubMed     Text format     Abstract available


  49. HAASE M, Kahle M, Janert M, Meier JJ, et al
    Basal rate tests (24 h fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles - a randomized controlled prospective trial.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12868.
    PubMed     Text format     Abstract available


  50. PARK YJ, Warnock GL, Ao Z, Safikhan N, et al
    Dual Role of IL-1beta in Islet Amyloid Formation and its beta-Cell Toxicity: Implications in Type 2 Diabetes and Islet Transplantation.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12873.
    PubMed     Text format     Abstract available


  51. HELLER SR, Bergenstal RM, White WB, Kupfer S, et al
    Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndromes: the EXAMINE trial.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12871.
    PubMed     Text format     Abstract available


  52. PARK SE, Lee BW, Kim JH, Lee WJ, et al
    Effect of gemigliptin on glycemic variability in patients with type 2 diabetes.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12869.
    PubMed     Text format     Abstract available


  53. HONG SM, Park CY, Hwang DM, Han KA, et al
    Efficacy and Safety of Adding Evogliptin versus Sitagliptin In Metformin-Treated Patients With Type 2 Diabetes: A 24-week Randomised, Controlled Trial With Open Label Extension.
    Diabetes Obes Metab. 2017 Jan 6. doi: 10.1111/dom.12870.
    PubMed     Text format     Abstract available


    December 2016
  54. AHN CH, Han KA, Yu JM, Nam JY, et al
    Efficacy and Safety of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Combination Treatment of Metformin and Sulfonylurea: a 24-week, multicenter, randomized, double-blind, place
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12866.
    PubMed     Text format     Abstract available


  55. GORDON J, McEwan P, Evans M, Puelles J, et al
    Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes.
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12867.
    PubMed     Text format     Abstract available


  56. MCEWAN P, Bennett H, Qin L, Bergenheim K, et al
    An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12865.
    PubMed     Text format     Abstract available


  57. YOON SA, Han BG, Kim SG, Han SY, et al
    Efficacy, Safety, and Albuminuria-Reducing Effect of Gemigliptin in Korean Type 2 Diabetes Patients with Moderate to Severe Renal Impairment: A 12-Week, Double-blind Randomized Study (the GUARD Study).
    Diabetes Obes Metab. 2016 Dec 25. doi: 10.1111/dom.12863.
    PubMed     Text format     Abstract available


  58. PENA MJ, de Zeeuw D, Andress D, Brennan JJ, et al
    The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
    Diabetes Obes Metab. 2016 Dec 25. doi: 10.1111/dom.12864.
    PubMed     Text format     Abstract available


  59. FORST T, Falk A, Andersen G, Fischer A, et al
    Effects of sequentially adding empagliflozin and linagliptin on alpha and beta cell function in type 2 diabetic patients on previous metformin treatment - An exploratory mechanistic study.
    Diabetes Obes Metab. 2016 Dec 23. doi: 10.1111/dom.12838.
    PubMed     Text format     Abstract available


  60. MOBINI R, Tremaroli V, Stahlman M, Karlsson F, et al
    Metabolic effects of Lactobacillus reuteri DSM 17938 in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2016 Dec 23. doi: 10.1111/dom.12861.
    PubMed     Text format     Abstract available


  61. KHENSIER K, Kashyap S
    Canagliflozin versus placebo for post-bariatric patients with persistent type II diabetes; a randomized controlled trial (CARAT).
    Diabetes Obes Metab. 2016 Dec 20. doi: 10.1111/dom.12860.
    PubMed     Text format     Abstract available


  62. YABE D, Iwasaki M, Kuwata H, Haraguchi T, et al
    SGLT2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative exploratory study.
    Diabetes Obes Metab. 2016 Dec 19. doi: 10.1111/dom.12848.
    PubMed     Text format     Abstract available


  63. KAPITZA C, Nowotny I, Lehmann A, Bergmann K, et al
    Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog(R) in subjects with type 1 diabetes.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12856.
    PubMed     Text format     Abstract available


  64. ARAKI E, Onishi Y, Asano M, Kim H, et al
    Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: DAISY trial.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12853.
    PubMed     Text format     Abstract available


  65. NAIK S, Belfort-DeAguiar R, Sejling AS, Szepietowska B, et al
    Evaluation of the Counter-regulatory Responses to Hypoglycemia in Patients with Type 1 Diabetes during Opiate Receptor Blockade with Naltrexone.
    Diabetes Obes Metab. 2016 Dec 17. doi: 10.1111/dom.12855.
    PubMed     Text format     Abstract available


  66. NIMRI R, Bratina N, Kordonouri O, Avbelj Stefanija M, et al
    MD-Logic Overnight Type 1 Diabetes Control in Home Settings: Multicenter, Multinational, Single blind, Randomized Trial.
    Diabetes Obes Metab. 2016 Dec 16. doi: 10.1111/dom.12852.
    PubMed     Text format     Abstract available


  67. HTIKE ZZ, Zaccardi F, Papamargaritis D, Webb DR, et al
    Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis.
    Diabetes Obes Metab. 2016 Dec 15. doi: 10.1111/dom.12849.
    PubMed     Text format     Abstract available


  68. DEJGAARD TF, Johansen NB, Frandsen CS, Asmar A, et al
    Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12841.
    PubMed     Text format     Abstract available


  69. HOME P
    Comment on Abd El Aziz et al, A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients, Diabetes Obesity Metab 2016; on line ahead of pub
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12842.
    PubMed     Text format    


  70. PETRIE JR, Chaturvedi N, Ford I, Hramiak I, et al
    Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial.
    Diabetes Obes Metab. 2016 Dec 9. doi: 10.1111/dom.12840.
    PubMed     Text format     Abstract available


    November 2016
  71. KAKU K, Sumino S, Katou M, Nishiyama Y, et al
    A randomized, double-blind, phase III study to evaluate efficacy and safety of once-daily treatment of alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 28. doi: 10.1111/dom.12837.
    PubMed     Text format     Abstract available


  72. PORKSEN N, Linnebjerg H, Garhyan P, Lam EC, et al
    Novel Hepato-Preferential Basal Insulin Peglispro (BIL) Does Not Differentially Affect Insulin Sensitivity Compared with Insulin Glargine in Patients with Type 1 and Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 26. doi: 10.1111/dom.12834.
    PubMed     Text format     Abstract available


  73. FRANDSEN CS, Dejgaard TF, Andersen HU, Holst JJ, et al
    Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study.
    Diabetes Obes Metab. 2016 Nov 21. doi: 10.1111/dom.12830.
    PubMed     Text format     Abstract available


  74. AHN CH, Kim EK, Min SH, Oh TJ, et al
    Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Lipid Metabolism and Endotoxemia after a High-Fat Meal in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 21. doi: 10.1111/dom.12831.
    PubMed     Text format     Abstract available


  75. MOKHLESI B, Grimaldi D, Beccuti G, Van Cauter E, et al
    Effect of One Week of CPAP Treatment of Obstructive Sleep Apnoea on 24-h Profiles of Glucose, Insulin and Counter-regulatory Hormones in Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Nov 17. doi: 10.1111/dom.12823.
    PubMed     Text format     Abstract available


  76. WEI W, Buysman E, Grabner M, Xie L, et al
    A Real-world Study of Treatment Patterns and Outcomes in US Managed-Care Patients With Type 2 Diabetes Initiating Injectable Therapies.
    Diabetes Obes Metab. 2016 Nov 17. doi: 10.1111/dom.12828.
    PubMed     Text format     Abstract available


  77. PREISS D, Dawed A, Welsh P, Heggie A, et al
    The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 13. doi: 10.1111/dom.12826.
    PubMed     Text format     Abstract available


  78. LI D, Wang T, Shen S, Fang Z, et al
    Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2016 Nov 12. doi: 10.1111/dom.12825.
    PubMed     Text format     Abstract available


  79. GHOLAP NN, Achana FA, Davies MJ, Ray KK, et al
    Long-term mortality following acute myocardial infarction among those with and without diabetes: A systematic review and meta-analysis of studies in the post reperfusion era.
    Diabetes Obes Metab. 2016 Nov 12. doi: 10.1111/dom.12827.
    PubMed     Text format     Abstract available


  80. RAYNER CK, Jones KL, Wu T, Horowitz M, et al
    Gut feelings about diabetes and GLP-1 receptor agonists - lessons to be learnt from studies in functional gastrointestinal disorders.
    Diabetes Obes Metab. 2016 Nov 9. doi: 10.1111/dom.12822.
    PubMed     Text format    


  81. VAN MUNSTER SN, van der Graaf Y, de Valk HW, Visseren FL, et al
    Effect modification in the relation between HbA1c and cardiovascular disease and mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Nov 2. doi: 10.1111/dom.12820.
    PubMed     Text format     Abstract available


  82. LAUGIER-ROBIOLLE S, Verges B, Le Bras M, Gand E, et al
    Glycemic control impacts the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
    Diabetes Obes Metab. 2016 Nov 2. doi: 10.1111/dom.12819.
    PubMed     Text format     Abstract available


  83. YABE D, Eto T, Shiramoto M, Irie S, et al
    Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2 arm parallel comparative, exploratory trial.
    Diabetes Obes Metab. 2016 Nov 1. doi: 10.1111/dom.12817.
    PubMed     Text format     Abstract available


  84. MITCHELL PL, Nachbar R, Lachance D, St-Pierre P, et al
    Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.
    Diabetes Obes Metab. 2016 Nov 1. doi: 10.1111/dom.12818.
    PubMed     Text format     Abstract available


    October 2016
  85. BLONDE L, Chava P, Dex T, Lin J, et al
    Predictors of type 2 diabetes patients' outcomes in the lixisenatide GetGoal clinical trials.
    Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12815.
    PubMed     Text format     Abstract available


  86. TUTTLE KR, Dwight McKinney T, Davidson JA, Anglin G, et al
    The Effects of Once Weekly Dulaglutide on Kidney Function in Patients with Type 2 Diabetes in Phase 2 and 3 Clinical Trials.
    Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12816.
    PubMed     Text format     Abstract available


  87. BROGLIO F, Mannucci E, Napoli R, Nicolucci A, et al
    Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: a meta-analysis from the GetGoal program.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12810.
    PubMed     Text format     Abstract available


  88. TINAHONES FJ, Gallwitz B, Nordaby M, Gotz S, et al
    Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12814.
    PubMed     Text format     Abstract available


  89. WU T, Xie C, Wu H, Jones KL, et al
    Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes.
    Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12812.
    PubMed     Text format     Abstract available


  90. MADJD A, Taylor MA, Delavari A, Malekzadeh R, et al
    Beneficial effects of replacing diet beverages with water on type 2 diabetic obese women following a hypo-energetic diet: A randomized, 24-week clinical trial.
    Diabetes Obes Metab. 2016 Oct 16. doi: 10.1111/dom.12793.
    PubMed     Text format     Abstract available


  91. ABD EL AZIZ MS, Kahle M, Meier JJ, Nauck MA, et al
    A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
    Diabetes Obes Metab. 2016 Oct 7. doi: 10.1111/dom.12804.
    PubMed     Text format     Abstract available


  92. SINGH S, Wright EE Jr, Kwan AY, Thompson JC, et al
    Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2016 Oct 7. doi: 10.1111/dom.12805.
    PubMed     Text format     Abstract available


  93. NAUCK MA, Kahle M, Baranov O, Deacon CF, et al
    A randomized controlled trial of adding the DPP-4 inhibitor sitagliptin to ongoing therapy with liraglutide (GLP-1 receptor agonist): Increases in intact GLP-1 and GIP, but no change in insulin, glucagon or plasma glucose following a mixed meal in pat
    Diabetes Obes Metab. 2016 Oct 6. doi: 10.1111/dom.12802.
    PubMed     Text format     Abstract available


  94. HEISE T, Zijlstra E, Nosek L, Rikte T, et al
    Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial.
    Diabetes Obes Metab. 2016 Oct 6. doi: 10.1111/dom.12803.
    PubMed     Text format     Abstract available


  95. ROHDE U, Federspiel CA, Vilmann P, Langholz E, et al
    The Impact of EndoBarrier Gastrointestinal Liner in Obese Patients with Normal Glucose Tolerance and Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Oct 3. doi: 10.1111/dom.12800.
    PubMed     Text format     Abstract available


  96. CUSI K, Sanyal AJ, Zhang S, Hoogwerf BJ, et al
    Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 2:50-58.
    PubMed     Text format     Abstract available


  97. MUDALIAR S, Henry RR, Ciaraldi TP, Armstrong DA, et al
    Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 2:17-24.
    PubMed     Text format     Abstract available


  98. GRUNBERGER G, Chen L, Rodriguez A, Tinahones FJ, et al
    A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naive patients with type 2 diabetes: the IMAGINE 6 trial.
    Diabetes Obes Metab. 2016;18 Suppl 2:34-42.
    PubMed     Text format     Abstract available


    September 2016
  99. CHOWDHURY TA, Srirathan D, Abraham G, Oei EL, et al
    COULD METFORMIN BE USED IN PATIENTS WITH DIABETES AND ADVANCED CHRONIC KIDNEY DISEASE?
    Diabetes Obes Metab. 2016 Sep 30. doi: 10.1111/dom.12799.
    PubMed     Text format     Abstract available


  100. MOREIRA-LUCAS TS, Duncan AM, Rabasa-Lhoret R, Vieth R, et al
    Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial.
    Diabetes Obes Metab. 2016 Sep 26. doi: 10.1111/dom.12794.
    PubMed     Text format     Abstract available


  101. MENSBERG P, Nyby S, Jorgensen PG, Storgaard H, et al
    Near-normalisation of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Sep 26. doi: 10.1111/dom.12797.
    PubMed     Text format     Abstract available


  102. LIM S, Han KA, Yu JM, Chamnan P, et al
    Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: a double-blind randomized controlled trial (INICOM study).
    Diabetes Obes Metab. 2016 Sep 13. doi: 10.1111/dom.12787.
    PubMed     Text format     Abstract available


  103. JOSSE RG, Majumdar SR, Zheng Y, Adler A, et al
    Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial.
    Diabetes Obes Metab. 2016 Sep 8. doi: 10.1111/dom.12786.
    PubMed     Text format     Abstract available


  104. TANG H, Cui W, Li D, Wang T, et al
    Sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2016 Sep 6. doi: 10.1111/dom.12785.
    PubMed     Text format     Abstract available


  105. BRAMLAGE P, Lanzinger S, Rathmann W, Gillessen A, et al
    Dyslipidaemia and its treatment in patients with type 2 diabetes - a joint analysis of the German DIVE and DPV registries.
    Diabetes Obes Metab. 2016 Sep 4. doi: 10.1111/dom.12783.
    PubMed     Text format     Abstract available


  106. VIEIRA A, Courtney M, Druelle N, Avolio F, et al
    beta-Cell replacement as a treatment for type 1 diabetes: an overview of possible cell sources and current axes of research.
    Diabetes Obes Metab. 2016;18 Suppl 1:137-43.
    PubMed     Text format     Abstract available


  107. REMEDI MS, Emfinger C
    Pancreatic beta-cell identity in diabetes.
    Diabetes Obes Metab. 2016;18 Suppl 1:110-6.
    PubMed     Text format     Abstract available


  108. BRERETON MF, Rohm M, Ashcroft FM
    beta-Cell dysfunction in diabetes: a crisis of identity?
    Diabetes Obes Metab. 2016;18 Suppl 1:102-9.
    PubMed     Text format     Abstract available


    August 2016
  109. JEFFERY N, Harries LW
    Beta cell differentiation status in type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 23. doi: 10.1111/dom.12778.
    PubMed     Text format     Abstract available


  110. CARLSON N, Hommel K, Olesen JB, Gerds TA, et al
    Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study.
    Diabetes Obes Metab. 2016 Aug 18. doi: 10.1111/dom.12764.
    PubMed     Text format     Abstract available


  111. FRIAS JP, Nakhle S, Ruggles JA, Zhuplatov S, et al
    Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2016 Aug 16. doi: 10.1111/dom.12763.
    PubMed     Text format     Abstract available


  112. TAKAHARA M, Shiraiwa T, Katakami N, Matsuoka TA, et al
    Preference in time of insulin injection in type 2 diabetic patients treated with once-daily long-acting insulin analog.
    Diabetes Obes Metab. 2016 Aug 9. doi: 10.1111/dom.12762.
    PubMed     Text format    


  113. PAUL SK, Shaw J, Montvida O, Klein K, et al
    Weight gain in insulin treated patients by BMI categories at treatment initiation: New evidence from real-world data in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 9. doi: 10.1111/dom.12761.
    PubMed     Text format     Abstract available


  114. VAJDA EG, Logan D, Lasseter K, Armas D, et al
    Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Aug 8. doi: 10.1111/dom.12752.
    PubMed     Text format     Abstract available


  115. BAIN SC, Feher M, Russell-Jones D, Khunti K, et al
    Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.
    Diabetes Obes Metab. 2016 Aug 5. doi: 10.1111/dom.12760.
    PubMed     Text format     Abstract available


  116. INAGAKI N, Araki E, Oura T, Matsui A, et al
    The combination of dulaglutide and biguanide reduced body weight in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Aug 3. doi: 10.1111/dom.12758.
    PubMed     Text format     Abstract available


  117. LINNEBJERG H, Lam EC, Zhang X, Seger ME, et al
    Duration of Action of Two Insulin Glargine Products, LY2963016 Insulin Glargine and Lantus(R) Insulin Glargine, in Subjects with Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2016 Aug 3. doi: 10.1111/dom.12759.
    PubMed     Text format     Abstract available


  118. JI LN, Pan CY, Lu JM, Li H, et al
    Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Diabetes Obes Metab. 2016;18:775-82.
    PubMed     Text format     Abstract available


    July 2016
  119. VELLECCO V, Mitidieri E, Gargiulo A, Brancaleone V, et al
    Vascular effects of Linagliptin in Non Obese Diabetic (NOD) mice are glucose-independent and involve positive modulation of Endothelial Nitric Oxide Synthase (eNOS)/caveolin-1 (CAV-1) pathway.
    Diabetes Obes Metab. 2016 Jul 27. doi: 10.1111/dom.12750.
    PubMed     Text format     Abstract available


  120. SMITS MM, Tonneijck L, Muskiet MH, Hoekstra T, et al
    Biliary effects of liraglutide and sitagliptin, a 12-week randomised placebo-controlled trial in type 2 diabetes patients.
    Diabetes Obes Metab. 2016 Jul 23. doi: 10.1111/dom.12748.
    PubMed     Text format     Abstract available


  121. ISHIHARA H, Yamaguchi S, Nakao I, Okitsu A, et al
    Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A multi-centre, randomized, placebo-controlled, double-blind study.
    Diabetes Obes Metab. 2016 Jul 20. doi: 10.1111/dom.12745.
    PubMed     Text format     Abstract available


  122. TANG HL, Li DD, Zhang JJ, Hsu YH, et al
    Lack of Evidence for a Harmful Effect of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2016 Jul 13. doi: 10.1111/dom.12742.
    PubMed     Text format     Abstract available


  123. GARG S, Selam JL, Bhargava A, Schloot N, et al
    Similar HbA1c Reduction and Hypoglycaemia with Variable- Vs Fixed-Time Dosing of Basal Insulin Peglispro (BIL) in Type 1 Diabetes: IMAGINE 7 Study.
    Diabetes Obes Metab. 2016 Jul 9. doi: 10.1111/dom.12740.
    PubMed     Text format     Abstract available


  124. GARG S, Dreyer M, Jinnouchi H, Mou J, et al
    A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1.
    Diabetes Obes Metab. 2016 Jul 8. doi: 10.1111/dom.12738.
    PubMed     Text format     Abstract available


  125. MATHIEU C, Herrera Mamolejo M, Gonzalez Gonzalez JG, Hansen L, et al
    Efficacy and Safety of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin Over 52 Weeks in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Jul 7. doi: 10.1111/dom.12737.
    PubMed     Text format     Abstract available


  126. BAILEY TS, Takacs R, Tinahones FJ, Rao PV, et al
    Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Diabetes Obes Metab. 2016 Jul 6. doi: 10.1111/dom.12736.
    PubMed     Text format     Abstract available


  127. SALSALI A, Kim G, Woerle HJ, Broedl UC, et al
    Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
    Diabetes Obes Metab. 2016 Jul 4. doi: 10.1111/dom.12734.
    PubMed     Text format     Abstract available


  128. AZAR ST, Echtay A, Wan Bebakar WM, Al Araj S, et al
    Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomised trial.
    Diabetes Obes Metab. 2016 Jul 4. doi: 10.1111/dom.12733.
    PubMed     Text format     Abstract available


  129. PARKINSON J, Tang W, Johansson CC, Boulton DW, et al
    Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016;18:685-92.
    PubMed     Text format     Abstract available


  130. TIRUCHERAI GS, LaCreta F, Ismat FA, Tang W, et al
    Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016;18:678-84.
    PubMed     Text format     Abstract available


    June 2016
  131. O'HARTE FP, Ng MT, Lynch AM, Conlon JM, et al
    Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    Diabetes Obes Metab. 2016 Jun 30. doi: 10.1111/dom.12713.
    PubMed     Text format     Abstract available


  132. DAVIES MJ, Russell-Jones D, Selam JL, Bailey TS, et al
    Basal insulin peglispro vs insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial.
    Diabetes Obes Metab. 2016 Jun 28. doi: 10.1111/dom.12712.
    PubMed     Text format     Abstract available


  133. VAN DER SANDE NG, Dorresteijn JA, Visseren FL, Dwyer JP, et al
    Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    Diabetes Obes Metab. 2016 Jun 23. doi: 10.1111/dom.12708.
    PubMed     Text format     Abstract available


  134. DAVIS TM, Badshah I, Chubb SA, Davis WA, et al
    Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2016 Jun 23. doi: 10.1111/dom.12710.
    PubMed     Text format     Abstract available


  135. EKSTROM N, Svensson AM, Miftaraj M, Franzen S, et al
    Cardiovascular Safety of Glucose-Lowering Agents as Add-on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR).
    Diabetes Obes Metab. 2016 Jun 10. doi: 10.1111/dom.12704.
    PubMed     Text format     Abstract available


  136. JENDLE J, Testa MA, Martin S, Jiang H, et al
    Continuous Glucose Monitoring in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide in Combination with Prandial Insulin Lispro - An AWARD-4 Substudy.
    Diabetes Obes Metab. 2016 Jun 9. doi: 10.1111/dom.12705.
    PubMed     Text format     Abstract available


  137. WYSHAM C, Guerci B, D'Alessio D, Jia N, et al
    Baseline Factors Associated with Glycaemic Response to Treatment with Once Weekly Dulaglutide in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12702.
    PubMed     Text format     Abstract available


  138. MAGNUSSEN LV, Glintborg D, Hermann P, Hougaard DM, et al
    Effect of testosterone on insulin sensitivity, oxidative metabolism, and body-composition in aging men with type 2 diabetes on metformin monotherapy.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12701.
    PubMed     Text format     Abstract available


  139. YOON KH, Nishimura R, Lee J, Crowe S, et al
    Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four Phase III trials.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12699.
    PubMed     Text format     Abstract available


  140. BERGENSTAL RM, Lunt H, Franek E, Travert F, et al
    A Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 3.
    Diabetes Obes Metab. 2016 Jun 6. doi: 10.1111/dom.12698.
    PubMed     Text format     Abstract available


    May 2016
  141. BLEVINS T, Pieber TR, Vega GC, Zhang S, et al
    Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination With Prandial Insulin Lispro, in Patients with Type 2 Diabetes: IMAGINE 4.
    Diabetes Obes Metab. 2016 May 28. doi: 10.1111/dom.12696.
    PubMed     Text format     Abstract available


  142. GERARDS MC, de Maar J, Steenbruggen TG, Hoekstra JB, et al
    Add-on treatment with intermediate-acting insulin versus sliding scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy - a randomized cross-over study.
    Diabetes Obes Metab. 2016 May 18. doi: 10.1111/dom.12694.
    PubMed     Text format     Abstract available


  143. APOVIAN C, Palmer K, Fain R, Perdomo C, et al
    Effects of Lorcaserin on Fat and Lean Mass Loss in Obese and Overweight Patients Without and With Type 2 Diabetes Mellitus: the BLOSSOM and BLOOM-DM Studies.
    Diabetes Obes Metab. 2016 May 13. doi: 10.1111/dom.12690.
    PubMed     Text format     Abstract available


  144. KAKU K, Enya K, Nakaya R, Ohira T, et al
    Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Diabetes Obes Metab. 2016 May 13. doi: 10.1111/dom.12693.
    PubMed     Text format     Abstract available


  145. MORROW LA, Hompesch M, Jacober SJ, Choi SL, et al
    Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.
    Diabetes Obes Metab. 2016 May 12. doi: 10.1111/dom.12691.
    PubMed     Text format     Abstract available


  146. KHUNTI K, Alsifri S, Aronson R, Berkovic MC, et al
    Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12689.
    PubMed     Text format     Abstract available


  147. BOUSTANI MA, Pittman Iv I, Yu M, Thieu VT, et al
    Comparable efficacy and safety of once weekly dulaglutide in patients with type 2 diabetes >/=65 and <65 years of age.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12687.
    PubMed     Text format     Abstract available


  148. PARRINELLO CM, Matsushita K, Woodward M, Wagenknecht LE, et al
    Risk prediction of major complications in persons with diabetes: The Atherosclerosis Risk in Communities Study.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12686.
    PubMed     Text format     Abstract available


  149. SKOW MA, Bergmann NC, Knop FK
    Diabetes and obesity treatment based on dual incretin receptor activation - "twincretins".
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12685.
    PubMed     Text format     Abstract available


  150. RODBARD HW, Seufert J, Aggarwal N, Cao A, et al
    Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12684.
    PubMed     Text format     Abstract available


  151. FU AZ, Sheehan J
    Treatment Intensification for Patients with Type 2 Diabetes and Poor Glycemic Control.
    Diabetes Obes Metab. 2016 May 10. doi: 10.1111/dom.12683.
    PubMed     Text format     Abstract available


  152. DEFRONZO RA, Chilton R, Norton L, Clarke G, et al
    Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    Diabetes Obes Metab. 2016;18:454-62.
    PubMed     Text format     Abstract available


  153. WILDING JP, Overgaard RV, Jacobsen LV, Jensen CB, et al
    Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Diabetes Obes Metab. 2016;18:491-9.
    PubMed     Text format     Abstract available


  154. MIKKELSEN KH, Allin KH, Knop FK
    Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature.
    Diabetes Obes Metab. 2016;18:444-53.
    PubMed     Text format     Abstract available


  155. HODGE RJ, Nunez DJ
    Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Diabetes Obes Metab. 2016;18:439-43.
    PubMed     Text format     Abstract available


  156. FREUDE S, Heise T, Woerle HJ, Jungnik A, et al
    Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Diabetes Obes Metab. 2016;18:483-90.
    PubMed     Text format     Abstract available


    April 2016
  157. DUTOUR A, Abdesselam I, Ancel P, Kober F, et al
    Exenatide decreases Liver fat content and Epicardial Adipose Tissue in Patients with obesity and Type 2 Diabetes: A prospective randomised clinical trial using Magnetic Resonance Imaging and Spectroscopy.
    Diabetes Obes Metab. 2016 Apr 23. doi: 10.1111/dom.12680.
    PubMed     Text format     Abstract available


  158. YANG S, Leslie WD, Morin SN, Majumdar SR, et al
    Antiresorptive Therapy and Newly-Diagnosed Diabetes in Women: A Historical Cohort Study.
    Diabetes Obes Metab. 2016 Apr 21. doi: 10.1111/dom.12678.
    PubMed     Text format     Abstract available


  159. ALLAS S, Delale T, Ngo N, Julien M, et al
    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531, a First-in-class Analogue of Unacylated Ghrelin (UAG), in Healthy, Overweight/Obese, and Type 2 Diabetes Subjects.
    Diabetes Obes Metab. 2016 Apr 10. doi: 10.1111/dom.12675.
    PubMed     Text format     Abstract available


  160. RATHMANN W, Bongaerts B, Kostev K
    Change in HbA1c after Initiating Second-Line Therapy in Type 2 Diabetes: A Primary Care Database Study.
    Diabetes Obes Metab. 2016 Apr 7. doi: 10.1111/dom.12673.
    PubMed     Text format     Abstract available


  161. ZANG L, Liu Y, Geng J, Luo Y, et al
    Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial.
    Diabetes Obes Metab. 2016 Apr 7. doi: 10.1111/dom.12674.
    PubMed     Text format     Abstract available


  162. KAZIERAD DJ, Bergman A, Tan B, Erion DM, et al
    Effects of multiple ascending doses of the glucagon receptor antagonist, PF-06291874, in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Apr 5. doi: 10.1111/dom.12672.
    PubMed     Text format     Abstract available


  163. MARI A, Del Prato S, Ludvik B, Milicevic Z, et al
    Differential effects of once weekly GLP-1 receptor agonist dulaglutide and metformin on pancreatic beta-cell and insulin sensitivity during a standardised test meal in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Apr 5. doi: 10.1111/dom.12671.
    PubMed     Text format     Abstract available


  164. ZACCARDI F, Webb DR, Htike ZZ, Youssef D, et al
    Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis.
    Diabetes Obes Metab. 2016 Apr 5. doi: 10.1111/dom.12670.
    PubMed     Text format     Abstract available


    March 2016
  165. WOLFFENBUTTEL BH, Gaal LV, Garcia SD, Han J, et al
    Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes.
    Diabetes Obes Metab. 2016 Mar 29. doi: 10.1111/dom.12669.
    PubMed     Text format     Abstract available


  166. LEITER LA, Cefalu WT, de Bruin TW, Xu J, et al
    Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
    Diabetes Obes Metab. 2016 Mar 24. doi: 10.1111/dom.12666.
    PubMed     Text format     Abstract available


  167. CAMERON D, Harris FM, Evans JM
    Patterns of self-monitoring of blood glucose (SMBG) in insulin-treated diabetes: analysis of a Scottish population over time.
    Diabetes Obes Metab. 2016 Mar 18. doi: 10.1111/dom.12662.
    PubMed     Text format     Abstract available


  168. ARODA VR, Bailey TS, Cariou B, Kumar S, et al
    The effect of adding insulin degludec in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
    Diabetes Obes Metab. 2016 Mar 18. doi: 10.1111/dom.12661.
    PubMed     Text format     Abstract available


  169. UMPIERREZ GE, Pantalone KM, Kwan AY, Zimmermann AG, et al
    Relationship between Weight Change and Glycaemic Control with Once Weekly Dulaglutide Treatment in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2016 Mar 11. doi: 10.1111/dom.12660.
    PubMed     Text format     Abstract available


  170. CLEMENS KK, Liu K, Shariff S, Schernthaner G, et al
    Secular trends in antihyperglycemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
    Diabetes Obes Metab. 2016 Mar 4. doi: 10.1111/dom.12658.
    PubMed     Text format     Abstract available


  171. NUNEZ DJ, Yao X, Lin J, Walker A, et al
    Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
    Diabetes Obes Metab. 2016 Mar 4. doi: 10.1111/dom.12656.
    PubMed     Text format     Abstract available


  172. DAVIS TM, Chubb SA, Bruce DG, Davis WA, et al
    Metabolic memory and all-cause death in community-based patients with type 2 diabetes:The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2016 Mar 3. doi: 10.1111/dom.12655.
    PubMed     Text format     Abstract available


  173. HEERSPINK HJ, Johnsson E, Gause-Nilsson I, Cain VA, et al
    Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers.
    Diabetes Obes Metab. 2016 Mar 3. doi: 10.1111/dom.12654.
    PubMed     Text format     Abstract available


  174. DAVIDSON JA, Orsted DD, Campos C
    Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase 3 trials.
    Diabetes Obes Metab. 2016 Mar 3. doi: 10.1111/dom.12653.
    PubMed     Text format     Abstract available


    February 2016
  175. SKOV J, Pedersen M, Holst JJ, Madsen B, et al
    Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
    Diabetes Obes Metab. 2016 Feb 22. doi: 10.1111/dom.12651.
    PubMed     Text format     Abstract available


  176. PARKINSON J, Tang W, Johansson CC, Boulton DW, et al
    Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Feb 17. doi: 10.1111/dom.12647.
    PubMed     Text format     Abstract available


  177. JOURDAN T, Godlewski G, Kunos G
    Endocannabinoid regulation of beta-cell functions: Implications for glycemic control and diabetes.
    Diabetes Obes Metab. 2016 Feb 16. doi: 10.1111/dom.12646.
    PubMed     Text format     Abstract available


  178. DEL PRATO S, Fleck P, Wilson C, Chaudhari P, et al
    Comparison of alogliptin and glipizide in composites of HbA1c reduction, no hypoglycaemia, and no weight gain in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2016 Feb 10. doi: 10.1111/dom.12643.
    PubMed     Text format     Abstract available


  179. ARONSON R, Reznik Y, Conget I, Castaneda JA, et al
    Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
    Diabetes Obes Metab. 2016 Feb 8. doi: 10.1111/dom.12642.
    PubMed     Text format     Abstract available


  180. MILICEVIC Z, Anglin G, Harper K, Konrad RJ, et al
    Low Incidence of Anti-Drug Antibodies in Type 2 Diabetes Patients Treated with Once Weekly GLP-1 Receptor Agonist Dulaglutide.
    Diabetes Obes Metab. 2016 Feb 5. doi: 10.1111/dom.12640.
    PubMed     Text format     Abstract available


    January 2016
  181. DUNGAN KM, Weitgasser R, Perez Manghi F, Pintilei E, et al
    A 24-week Study to Evaluate the Efficacy and Safety of Once Weekly Dulaglutide Added on to Glimepiride in Type 2 Diabetes (AWARD-8).
    Diabetes Obes Metab. 2016 Jan 22. doi: 10.1111/dom.12634.
    PubMed     Text format     Abstract available


  182. HONG S, Park CY, Han KA, Chung CH, et al
    Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: A 24-week multicenter, randomized, double-blind, placebo-controlled phase III trial.
    Diabetes Obes Metab. 2016 Jan 9. doi: 10.1111/dom.12631.
    PubMed     Text format     Abstract available


  183. PETTUS J, McNabb B, Eckel RH, Skyler JS, et al
    The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Diabetes Obes Metab. 2016 Jan 8. doi: 10.1111/dom.12629.
    PubMed     Text format     Abstract available


  184. HADJIYIANNI I, Dahl D, Lacaya LB, Pollom RK, et al
    The efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
    Diabetes Obes Metab. 2016 Jan 7. doi: 10.1111/dom.12628.
    PubMed     Text format     Abstract available


  185. GALLAGHER H, Suckling RJ
    Diabetic nephropathy - where are we on the journey from pathophysiology to treatment?
    Diabetes Obes Metab. 2016 Jan 7. doi: 10.1111/dom.12630.
    PubMed     Text format     Abstract available


  186. RANJAN A, Schmidt S, Madsbad S, Holst JJ, et al
    Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Diabetes Obes Metab. 2016 Jan 7. doi: 10.1111/dom.12627.
    PubMed     Text format     Abstract available


  187. KHUNTI K, Nikolajsen A, Thorsted BL, Andersen M, et al
    Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin.
    Diabetes Obes Metab. 2016 Jan 7. doi: 10.1111/dom.12626.
    PubMed     Text format     Abstract available


  188. WILKIN T, Greene S, McCrimmon R
    Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (adAPT 1).
    Diabetes Obes Metab. 2016;18:3-5.
    PubMed     Text format    


    December 2015
  189. FOROUHI NG, Menon RK, Sharp SJ, Mannan N, et al
    The effects of vitamin D or D supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomised double-blind placebo-controlled trial.
    Diabetes Obes Metab. 2015 Dec 23. doi: 10.1111/dom.12625.
    PubMed     Text format     Abstract available


  190. YU M, Van Brunt K, Varnado OJ, Boye KS, et al
    Patient-reported outcome results in patients with type 2 diabetes treated with once weekly dulaglutide: data from the AWARD Phase 3 clinical trial programme.
    Diabetes Obes Metab. 2015 Dec 22. doi: 10.1111/dom.12624.
    PubMed     Text format     Abstract available


  191. SEUFERT J, Bailey T, Christensen SB, Nauck M, et al
    The impact of diabetes duration on achieved HbA1c, FPG and body weight reductions with liraglutide treatment for up to 28 weeks: meta-analysis of seven phase 3 trials.
    Diabetes Obes Metab. 2015 Dec 18. doi: 10.1111/dom.12623.
    PubMed     Text format     Abstract available


  192. PANG J, Chan DC, Hamilton SJ, Tenneti VS, et al
    Effect of Niacin on Triglyceride-Rich Lipoprotein Apolipoprotein B-48 Kinetics in Statin-Treated Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2015 Dec 18. doi: 10.1111/dom.12622.
    PubMed     Text format     Abstract available


  193. STIRBAN AO, Andjelkovic M, Heise T, Nosek L, et al
    Aleglitazar, a Dual Peroxisome Proliferator-Activated Receptor -alpha/gamma Agonist, Improves Insulin Sensitivity, Glucose Control and Lipids in People with Type 2 Diabetes: Findings from a Randomized, Double-blind Trial.
    Diabetes Obes Metab. 2015 Dec 11. doi: 10.1111/dom.12620.
    PubMed     Text format     Abstract available


  194. MATSUHISA M, Koyama M, Cheng X, Takahashi Y, et al
    New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
    Diabetes Obes Metab. 2015 Dec 11. doi: 10.1111/dom.12619.
    PubMed     Text format     Abstract available


  195. TERAUCHI Y, Koyama M, Cheng X, Takahashi Y, et al
    New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drug(s): glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Diabetes Obes Metab. 2015 Dec 11. doi: 10.1111/dom.12618.
    PubMed     Text format     Abstract available


  196. POLIDORI D, Capuano G, Qiu R
    Apparent Subadditivity of the Efficacy of Initial Combination Treatments for Type 2 Diabetes Is Largely Explained by the Impact of Baseline HbA1c on Efficacy.
    Diabetes Obes Metab. 2015 Dec 11. doi: 10.1111/dom.12615.
    PubMed     Text format     Abstract available


  197. WOODWARD M, Hirakawa Y, Kengne AP, Matthews DR, et al
    Prediction of ten-year vascular risk amongst patients with diabetes: the AD-ON risk score.
    Diabetes Obes Metab. 2015 Dec 11. doi: 10.1111/dom.12614.
    PubMed     Text format     Abstract available


  198. SMITS MM, Tonneijck L, Muskiet MH, Kramer MH, et al
    GLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in type 2 diabetes patients: a randomised trial.
    Diabetes Obes Metab. 2015 Dec 6. doi: 10.1111/dom.12612.
    PubMed     Text format     Abstract available


    November 2015
  199. RODBARD HW, Cariou B, Pieber TR, Endahl LA, et al
    Treatment intensification with an insulin degludec (IDeg)-insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase 3 trial.
    Diabetes Obes Metab. 2015 Nov 23. doi: 10.1111/dom.12609.
    PubMed     Text format     Abstract available


  200. ERDMANN E, Harding S, Lam H, Perez A, et al
    10-Year Observational Follow-Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
    Diabetes Obes Metab. 2015 Nov 23. doi: 10.1111/dom.12608.
    PubMed     Text format     Abstract available


  201. VATIER C, Fetita S, Boudou P, Tchankou C, et al
    One-year metreleptin treatment improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Diabetes Obes Metab. 2015 Nov 20. doi: 10.1111/dom.12606.
    PubMed     Text format     Abstract available


  202. GRANDY S, Sternhufvud C, Ryden A, Sugg J, et al
    Patient-Reported Outcomes Among Type 2 Diabetes Mellitus Patients Treated with Dapagliflozin in Triple Therapy Regimen for 52 Weeks.
    Diabetes Obes Metab. 2015 Nov 5. doi: 10.1111/dom.12604.
    PubMed     Text format     Abstract available


  203. ROHDE U, Hedback N, Gluud LL, Vilsboll T, et al
    Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: Systematic review and meta-analysis.
    Diabetes Obes Metab. 2015 Nov 5. doi: 10.1111/dom.12603.
    PubMed     Text format     Abstract available


  204. ODAWARA M, Miyagawa J, Iwamoto N, Takita Y, et al
    Once weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases HbA1c compared with once daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Diabetes Obes Metab. 2015 Nov 2. doi: 10.1111/dom.12602.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: